Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trileptal Off-Label Promotion Subject Of Philadelphia U.S. Attorney Subpoena

This article was originally published in The Pink Sheet Daily

Executive Summary

Anti-epileptic understood to be subject of civil and criminal investigation into Novartis’ marketing practices. Trileptal subpoena is pursuant to HIPAA privacy provisions of 2003, company says.

You may also be interested in...



Federal Prosecutors Are Watching Rx Firms’ Handling Of Patient Info

Federal prosecutors are likely to bring suits against pharmaceutical manufacturers alleging violations of patient privacy provisions under the Health Insurance Portability & Accountability Act, Assistant U.S. Attorney Michael Loucks said June 22 at an IIR conference in Boston

Pfizer Will Monitor Off-Label Drug Use And Report To IG Under Neurontin Settlement

Corporate integrity agreement will be carefully studied in pharmaceutical industry given uncertainties surrounding off-label promotion rules. Pfizer agrees to establish clear policies and keep close tabs on off-label use – but the agreement does not define prohibited or permitted activities.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel